Gefitinib-d6 manufacturers
- Gefitinib-D6
-
- $0.00 / 1mg
-
2026-05-11
- CAS:1228664-49-0
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | Gefitinib-d6 Basic information |
| Product Name: | Gefitinib-d6 | | Synonyms: | Gefitinib-d6;Hexadeuterated gefitinib;[2H6]-Gefitinib;N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy-1,1,2,2,3,3-d6]-4-quinazolinamine;D6-Gefitinib | | CAS: | 1228664-49-0 | | MF: | C22H24ClFN4O3 | | MW: | 446.91 | | EINECS: | | | Product Categories: | | | Mol File: | 1228664-49-0.mol |  |
| | Gefitinib-d6 Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMF: 20 mg/ml,DMSO: 20 mg/ml,DMSO:PBS (pH 7.2) (1:1): 0.5 mg/ml,Ethanol: 0.3 mg/ml | | form | A solid | | color | White to off-white |
| | Gefitinib-d6 Usage And Synthesis |
| Description | Gefitinib-d6 is intended for use as an internal standard for the quantification of gefitinib by GC- or LC-MS. Gefitinib is an EGFR inhibitor (IC50s = 0.023-0.079 μM). It inhibits colony formation of GEO colon, ZR-75-1 and MCF-10A breast, and OVCAR-3 ovarian cancer cell lines in soft agar assays (IC50s = 0.2-0.4 μM). Gefitinib (0.1 to 1 μM) induces apoptosis and inhibits EGFR autophosphorylation in the same cells. In vivo, gefitinib (1.25, 2.5, and 5 mg/kg) reduces tumor volume and increases survival in a GEO mouse xenograft model. Formulations containing gefitinib have been used in the treatment of non-small cell lung cancer (NSCLC). | | Uses | Gefitinib-d6 is the labeled version of Gefitinib (G304000), which is an antineoplastic. | | References | [1] JOHN MENDELSOHN Jose B. The EGF receptor family as targets for cancer therapy[J]. Oncogene, 2000, 19 56: 6550-6565. DOI: 10.1038/sj.onc.1204082
[2] F CIARDIELLO. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.[J]. Clinical Cancer Research, 2000, 6 5: 2053-2063.
|
| | Gefitinib-d6 Preparation Products And Raw materials |
|